Marché mondial du traitement du syndrome de Brugada – Tendances et prévisions de l'industrie jusqu'en 2028

Analyse et perspectives du marché : marché mondial du traitement du syndrome de Brugada

Le marché mondial du traitement du syndrome de Brugada devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse le marché pour prévoir une croissance à un TCAC de 5,60 % au cours de la période de prévision mentionnée ci-dessus.

Le syndrome de Brugada est une maladie cardiovasculaire génétique rare qui provoque un rythme cardiaque irrégulier et dangereux. Il se caractérise par des perturbations affectant le système électrique du cœur. Il est dû à la perturbation des ions sodium ou potassium dans les cellules du cœur. Cela provoque une perturbation supplémentaire des impulsions électriques et entraîne des rythmes cardiaques très rapides et potentiellement mortels. Les symptômes courants de cette maladie comprennent des convulsions , des étourdissements, des évanouissements, des halètements et des battements cardiaques irréguliers.

L’augmentation de la prévalence du syndrome de Brugada, l’augmentation des dépenses de santé, la demande thérapeutique croissante, les progrès des technologies de diagnostic et les initiatives gouvernementales croissantes de sensibilisation sont les facteurs qui élargiront le marché mondial du traitement du syndrome de Brugada.

L'augmentation des activités de R&D, la demande croissante de thérapies avancées et l'attention accrue des grandes sociétés pharmaceutiques vers de nouvelles thérapies de traitement offriront des opportunités bénéfiques pour le marché mondial du traitement du syndrome de Brugada au cours de la période de prévision 2021-2028.

La pénurie d'experts en soins de santé cardiovasculaire, le coût élevé du traitement et le manque de sensibilisation aux maladies rares sont les facteurs qui entraveront la croissance du marché et constitueront un défi supplémentaire pour le marché mondial du traitement du syndrome de Brugada au cours de la période de prévision mentionnée ci-dessus.

This brugada syndrome treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global brugada syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Brugada Syndrome Treatment Market Scope and Market Size

The brugada syndrome treatment market is segmented on the basis of treatment, dosage, route of administration, diagnosis, end-users, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of treatment, the brugada syndrome treatment market is segmented into implantable cardioverter-defibrillator (ICD) and drug therapy. Drug therapy has been further sub-segmented into antiarrhythmic drugs, psychotropic drugs, anesthetics/analgesics, and others. Antiarrhythmic drugs have been further divided into ajmaline, allapinin, ethacizine, flecainide, pilsicainide, procainamide, propafenone, and other. Psychotropic drugs have been further divided into amitriptyline, clomipramine, desipramine, lithium, loxapine, nortriptyline, trifluoperazine, and others. Anesthetics/analgesics have been further divided into bupivacaine, procaine, propofol, and others.
• On the basis of dosage, the brugada syndrome treatment market is segmented into tablet, solution and others.
• On the basis of route of administration, the brugada syndrome treatment market is segmented into oral, intravenous, and others.
• On the basis of diagnosis, the brugada syndrome treatment market is segmented into electrocardiogram, electrophysiology (EP) test, genetic testing and others.
• On the basis of end-users, the brugada syndrome treatment market is segmented into clinic, hospital, and others.
• The brugada syndrome treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy, and online pharmacy.

Global Brugada Syndrome Treatment Market Country Level Analysis

Global brugada syndrome treatment market is analyzed and market size information is provided by the country, treatment, dosage, route of administration, diagnosis, end-users, and distribution channel as referenced above.

The countries covered in the global brugada syndrome treatment market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the brugada syndrome treatment market due to the presence of major key players, well-developed healthcare sector, increasing prevalence of disease, and increasing awareness towards health in this region. Global brugada syndrome treatment market in the Asia-Pacific and Europe is expected to grow during the forecast period due to the increasing research and development activities, rise in number of insurance players, rising investment in the healthcare sector, and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Global brugada syndrome treatment market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Brugada Syndrome Treatment Market Share Analysis

Global brugada syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global brugada syndrome treatment market.

Les principaux acteurs couverts dans le rapport sur le marché mondial du traitement du syndrome de Brugada sont Boston Scientific Corporation, LivaNova PLC, Medtronic, Abbott, Edwards Lifesciences Corporation, Sun Pharmaceutical Industries Ltd., Novartis AG, ClearPoint Neuro, Inc., HeartSine Technologies LLC, GeneDx, Inc, GENERAL ELECTRIC COMPANY, Pfizer Inc., Lilly, GlaxoSmithKline plc et Taj Pharmaceuticals Limited, entre autres acteurs nationaux et mondiaux. Les données sur les parts de marché sont disponibles séparément pour le monde, l'Amérique du Nord, l'Europe, l'Asie-Pacifique (APAC), le Moyen-Orient et l'Afrique (MEA) et l'Amérique du Sud. Les analystes de DBMR comprennent les atouts concurrentiels et fournissent une analyse concurrentielle pour chaque concurrent séparément.

SKU-64274